Si Chuan Venture Capital

Si Chuan Venture Capital is a fund management and investment firm that focuses on providing financial support to promising businesses and startups. With a strong emphasis on strategic investments, the company plays a crucial role in fostering innovation and growth within the market. Through careful analysis and meticulous planning, Si Chuan Venture Capital aims to generate long-term value for both its investors and the companies it supports. By leveraging its expertise and resources, the firm actively contributes to the success and development of emerging enterprises, ultimately seeking to create a prosperous and sustainable business ecosystem.

Zhang Fan

Investment Director

Yu Yan

General Manager

19 past transactions

RootPath Genomics

Venture Round in 2025
RootPath Genomics, Inc. is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company specializes in developing a next-generation T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of individual immune cells, RootPath aims to enhance immune responses and improve cell therapy efficacy. Its innovative technologies allow for precise monitoring and modulation of the immune system, which is intended to revolutionize the diagnosis and treatment of cancer.

Geneus

Series B in 2025
Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Gene Vector

Venture Round in 2025
Chengdu Genevector Biotechnology Co., Ltd. is a biotechnology firm specializing in the research and development of adeno-associated virus (AAV) gene therapy drugs. The company is dedicated to creating innovative therapies targeting a range of medical conditions, including ophthalmic diseases, neuromuscular disorders, hereditary diseases, cardiovascular and cerebrovascular diseases, as well as neurodegenerative diseases. Genevector aims to establish a comprehensive technology chain for AAV drug development, facilitating the delivery of novel biotherapy solutions to address significant health challenges.

New Radiomedicine Technology

Series C in 2024
Founded in 2016, New Radiomedicine Technology is a Chinese company specializing in the research, manufacture, and sales of medical isotopes. It provides services for malignant tumor diagnosis and treatments, offering radionuclides medicine technology support and consulting.

Baoling Bio

Series B in 2023
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.

Gachun Biotech

Series A in 2023
Gachun Biotech is a pharmaceutical intermediates industrialization platform that focuses on APIs, or pharmaceutical intermediates.

Fibresound Technology

Seed Round in 2023
Fibresound Technology is a chip development company that specializes in the R&D and design of piezoelectric MEMS microphone chips.

Illumax

Series A in 2023
Illumax is a company that specialises in the research and development of single-serve chemiluminescence, single-serve flow fluorescence, and laboratory automation technologies. It also offers the industry an open ecological platform for chemiluminescence and flow fluorescence.

RiVAI

Venture Round in 2023
RiVAI Technologies is a prominent developer of high-performance RISC-V based CPUs and customized system-on-chip (SoC) designs. The company specializes in creating advanced artificial intelligence chips tailored for Internet of Things (IoT) applications, serving a diverse range of sectors such as wearable technology, smart home devices, security systems, agriculture, and consumer electronics. By leveraging RISC-V, an open standard instruction set architecture, RiVAI enables its clients to achieve low-power and high-performance processing capabilities essential for modern computing demands, from edge devices to data centers.

Baoling Bio

Series A in 2021
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.

Ghostcloud

Series B in 2019
Ghostcloud, officially known as Chengdu Elf Cloud Technology Co., Ltd., is a prominent player in the field of container virtualization and cloud computing, situated in Chengdu Tianfu Software Park. The company specializes in developing a Docker-based hybrid cloud platform that offers enterprises a range of services, including private cloud management and big data infrastructure. By providing cloud computing infrastructure, container cloud PaaS/CaaS platforms, and tailored private and hybrid cloud solutions, Ghostcloud enables businesses across various industries to optimize their operations. Its offerings are designed to reduce hardware costs, enhance operational efficiency, facilitate rapid product iteration, and improve system security, making it a key contributor to the digital transformation of enterprises in China and beyond.

Jinglingyun Xiao

Series A in 2019
Jinglingyun Xiao builds a SaaS cloud platform for education and training institutions.

Hyperway Pharm

Angel Round in 2019
Hyperway Pharm is a pharmaceutical research and development enterprise specializing in the development and production of small-molecule drugs aimed at treating various diseases. The company is dedicated to establishing a world-class research and development platform, emphasizing innovation in small molecule drugs and high-end active pharmaceutical ingredients (APIs). Its core team, comprised of high-end talent from Chengdu, Sichuan Province, boasts extensive experience with prominent Fortune 500 companies and well-known domestic pharmaceutical firms. This expertise allows Hyperway Pharm to navigate the complexities of drug development effectively. The company has successfully developed several innovative drugs that are currently in clinical trials, alongside a range of high-quality generic drugs, ensuring a commitment to safety and efficacy in its offerings.

Stork Healthcare

Series A in 2019
Stork Healthcare is a company focused on the development of portable, non-invasive diagnostic ultrasound medical equipment. It offers a range of innovative handheld ultrasound products designed for various applications, including liver disease diagnosis, cervical vascular screening, and thyroid screening. The company has created its own original imaging platform, incorporating advanced technologies such as elastic imaging and 3D Doppler spectrum imaging. By providing instant, analysis-ready images, Stork Healthcare enables healthcare professionals to deliver more effective treatment to their patients, enhancing the overall quality of care.

EVspeak

Series A in 2019
EVspeak is a new energy vehicle intelligent networked software and hardware integrated solution provider. Based on vehicle intelligent hardware and cloud multi-source heterogeneous big data cloud control platform, it provides customers with car road cloud collaborative unmanned driving. A number of new energy vehicle intelligent network services and related products, including vehicle life cycle management, intelligent networked software and hardware solutions, and new energy vehicle electronic control system development.

Alinket

Series D in 2018
Alinket is a technology company that provides integrated Internet of Things solutions, including IoT controllers, IoT middleware, cloud access technology, and application technology, and it offers sensor, audio, health, and medical kits to support connected devices and data-driven applications across industries.

Shanghai Monolith Technology Co.,Ltd

Series A in 2017
Shanghai Monolith Technology Co.,Ltd provides intelligent manufacturing system solutions to logistics and manufacturing sectors.

Oriented Knowledge

Series A in 2017
Oriented Knowledge is an AI-based education service provider.

Sichuan Jiuzhou Beidou Daohang Yuweizhi Fuwu Co.

Series A in 2015
Sichuan Jiuzhou Beidou Daohang Yuweizhi Fuwu is a provider of automobile navigation and location services. They serve the electronic information industry, mainly providing military information, equipment, and systems, as well as military industrial fusion digital intelligence software and hardware products and services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.